Abbott ID NOW: PCR, Antigen, or Something Else?

The Abbott ID NOW is a molecular test, but it is not PCR. It uses a technology called isothermal nucleic acid amplification, which means it copies genetic material from a pathogen to detect infection, just like PCR does, but through a fundamentally different process. The specific method is called nicking enzyme amplification reaction, or NEAR, and understanding where it sits between traditional PCR and rapid antigen tests explains a lot about when the device shines and when it falls short.

What NEAR Technology Actually Does

Standard PCR works by heating and cooling a sample through repeated temperature cycles. Each cycle doubles the target DNA or RNA, and after about 30 to 40 cycles the signal is strong enough to detect. That thermal cycling is powerful and extremely sensitive, but it requires specialized lab equipment and takes time, often several hours from sample to result when you include transport and processing.

The ID NOW skips the temperature cycling entirely. Its NEAR process runs at a single constant temperature, using a nicking enzyme that cuts one strand of a double-stranded DNA copy, allowing a new strand to be synthesized from the nick point. This happens over and over in a chain reaction, producing billions of copies of the target sequence in minutes rather than hours. Because no thermal cycler is needed, the device is small enough to sit on a countertop in an emergency department or urgent care clinic.

Isothermal amplification methods like NEAR overcome the complexity of traditional molecular diagnostics and are not subject to the temperature-cycling limitations of PCR, relying instead on enzymes to efficiently amplify targets in a very short time.¹ These isothermal approaches function at a constant temperature without requiring thermal cycler equipment, which simplifies the amplification process and makes them a viable alternative to PCR, especially in settings where speed and simplicity matter most.²

Why It Is Not an Antigen Test Either

Rapid antigen tests work on a completely different principle. They detect proteins on the surface of a virus, not its genetic material. You swab your nose, the sample flows across a test strip, and antibodies on the strip grab viral proteins if they are present. No amplification of any kind happens. This makes antigen tests fast and cheap but limits how much virus needs to be in the sample before the test can pick it up.

The ID NOW, by contrast, amplifies the virus’s RNA. Even a small amount of genetic material gets copied millions of times over, making the test far more sensitive than a standard antigen strip. That is the core distinction: antigen tests look for what the virus is made of, while the ID NOW (like PCR) looks for the virus’s genetic instructions and amplifies them. The ID NOW is classified as a rapid molecular point-of-care test for qualitative detection of SARS-CoV-2, sitting firmly in the molecular category alongside PCR even though its underlying chemistry is different.³

So the ID NOW occupies a middle ground in terms of how people think about testing. It is molecular like PCR, meaning it detects and amplifies nucleic acid. But it is rapid and portable like an antigen test, designed for point-of-care use rather than a central laboratory. If you are trying to place it in one of the two familiar buckets, molecular is the correct one.

How Sensitive Is It Compared to Lab-Based PCR?

This is where the trade-off for speed becomes concrete. The ID NOW is genuinely good at detecting infections, but it is not quite as sensitive as a full RT-PCR run in a laboratory. A systematic review and meta-analysis looking at 15 studies found that the ID NOW’s sensitivity was lower than RT-PCR in 14 of those 15 studies. When compared against a composite reference standard, the ID NOW’s sensitivity ranged from about 44% to 94% across studies, while the RT-PCR tests ranged from 91% to 100%.⁴

That wide range, 44% to 94%, is not random noise. Reports on ID NOW performance have been mixed, likely due to variations in patient groups, how samples were collected and handled, and differences in study design.⁵ The device performs significantly better in some circumstances than others, and understanding what drives that variability is more useful than fixating on a single sensitivity number.

Viral Load Is the Biggest Factor

The single most important variable in ID NOW accuracy is how much virus is in the sample. When someone has a high viral load, meaning they are typically in the early symptomatic phase of infection and shedding a lot of virus, the ID NOW performs very well. When viral load is low, perhaps because someone was tested very early before the infection ramped up, or late when viral shedding is declining, the test is more likely to miss it.

One emergency department study quantified this clearly. Cases that the ID NOW missed (false negatives) had substantially higher cycle threshold values on confirmatory PCR than the cases it caught. The median cycle threshold for false negatives was about 37, compared to about 26 for true positives, indicating much less virus in the missed samples. When restricted to PCR-positive cases with cycle thresholds below 35, the ID NOW’s sensitivity jumped to about 92%.⁶

A larger study of the updated ID NOW COVID-19 2.0 assay found similar patterns in symptomatic patients. Overall agreement with RT-PCR was about 92% in symptomatic individuals, but accuracy climbed steadily with higher viral loads. At moderate to high viral loads (cycle threshold values of 30 or below), agreement reached over 99%.³ In practical terms, this means the ID NOW is very reliable at catching the people who are most infectious. The cases it tends to miss are those with borderline-detectable virus levels, who are generally less likely to transmit the infection to others.

Symptomatic Versus Asymptomatic Testing

Whether the person being tested has symptoms turns out to matter quite a bit, and not just because symptomatic people tend to have higher viral loads. A large population-level validation study found that ID NOW sensitivity was highest among symptomatic individuals presenting to community collection sites, reaching about 93%. For asymptomatic individuals tested during community outbreak investigations, sensitivity dropped to around 74%. Specificity, the ability to correctly identify people who were not infected, was above 99% in every population tested.⁷

This has real implications for how the test should be used. For someone who walks into an emergency department with a cough and fever, the ID NOW is a genuinely useful rapid tool. For mass screening of asymptomatic people, say at a workplace or before a large gathering, the miss rate is high enough that a negative result on its own does not provide the same level of reassurance. Many clinical sites during the pandemic used the ID NOW as a first-pass screen, sending negative results for confirmatory PCR when clinical suspicion remained high.

Swab Type and Sample Handling

One of the less intuitive findings from the pandemic testing era was how much the type of swab and the specimen collection method affected ID NOW results. A comparative study found that ID NOW performance was substantially worse with nasal swabs compared to nylon-flocked nasopharyngeal swabs. The population being tested also mattered: people who had been chronically positive for SARS-CoV-2 (carrying low levels of residual virus rather than being acutely infected) produced far more false negatives than acutely infected individuals.⁸

This is a case where the device’s sensitivity limitations were at least partly a sample-quality problem rather than a chemistry problem. The ID NOW demonstrated comparable analytical sensitivity to other nucleic acid amplification platforms in controlled conditions; what dragged its real-world performance down in some studies was the combination of suboptimal specimen type and patient populations with low viral loads. When labs and clinics paid close attention to collection technique and used the recommended swab types, results improved.

Speed and What It Means for Emergency Departments

The ID NOW’s main selling point has always been speed. Results typically come back in about 13 minutes or less, compared to hours for a standard RT-PCR sent to a central lab. In emergency department settings, this translates into concrete workflow benefits.

One medical center found that despite the device’s sensitivity limitations, it was capable of providing near-real-time results for about 10% of symptomatic patients presenting to the emergency department, which improved patient management and workflow.⁹ Knowing a patient’s COVID status within minutes rather than hours meant faster decisions about isolation, room assignments, and treatment pathways.

The financial side of this is worth noting. A hospital cost analysis found that the ID NOW test itself was somewhat more expensive per unit than an RT-PCR (roughly €50 versus €41 in their pricing), but the rapid turnaround eliminated the need for costly precautionary measures while waiting for results. For trauma patients needing surgery, the savings from not having to maintain full isolation protocols and delay operating room access amounted to over €2,600 per patient. Even for patients not requiring surgery, the avoided costs ran about €729 per admission.¹⁰ The per-test cost is a fraction of the system costs that pile up when you are waiting four or six hours for a lab result.

Beyond COVID Testing

While the pandemic put the ID NOW on the map for most people, the platform was designed as a general-purpose rapid molecular testing system, not a single-use COVID device. Abbott has developed ID NOW assays for influenza A/B and respiratory syncytial virus (RSV) as well. All of these assays use the same isothermal nucleic acid amplification technology and are waived for point-of-care use in the United States, meaning they can be run by trained staff outside of a traditional laboratory setting.¹¹

The flu and RSV assays matter because rapid molecular testing for respiratory viruses has the potential to change prescribing decisions in real time. A clinician who knows within 15 minutes that a patient has influenza A can prescribe antivirals like oseltamivir during the narrow window when they are most effective, rather than starting them empirically or waiting for lab confirmation the next day. For RSV, particularly in young children and older adults, rapid identification helps guide isolation decisions and supportive care without the delays of send-out testing.

The platform’s versatility is part of its appeal to clinics and hospitals. A single countertop instrument that can run tests for COVID, flu, and RSV using the same basic workflow simplifies training and reduces the need for multiple testing systems. The trade-off remains the same across all these assays: you gain speed and simplicity but give up some sensitivity compared to a lab-based PCR platform.

Viral Mutations and the Accuracy Question

One concern with any molecular test, whether it is PCR or isothermal amplification, is what happens when the virus mutates in the region the test targets. All molecular tests work by matching short sequences of genetic material (primers and probes) to specific parts of the virus’s genome. If the virus mutates in those binding sites, the test can lose accuracy regardless of the underlying technology.

SARS-CoV-2 has proven highly susceptible to mutations in its RNA genome, with different subvariants emerging continuously since its discovery. Any mutation in the target primer or probe-binding site has the potential to reduce test accuracy, and this applies to both RT-PCR and isothermal-based technologies like the ID NOW.¹² This is one reason test manufacturers periodically update their assays and why regulatory agencies monitor whether existing tests remain accurate against circulating variants.

The ID NOW COVID-19 assay targets a region of the virus’s RdRp gene. Whether a specific variant affects the test depends on whether mutations occur in that particular target region. Throughout the pandemic, the assay maintained clinical utility across the major variants, though individual variant waves prompted validation studies to confirm that performance held. This ongoing need for variant monitoring applies equally to lab-based PCR tests, so it is not a weakness unique to isothermal platforms.

When a Positive Is Not Really a Positive

The ID NOW’s specificity, its ability to correctly identify people who are not infected, has been consistently excellent. Across studies, specificity generally exceeds 99%.⁶ That means false positives are rare. When the test says you are infected, it is almost always right.

However, no test has perfect specificity, and in low-prevalence settings the math of false positives can get tricky. If only one in a thousand people being tested is actually infected, even a 99.5% specificity rate means that a nontrivial fraction of positive results could be false alarms. This is a general feature of diagnostic testing, not specific to the ID NOW, but it is worth keeping in mind when interpreting results from mass screening programs where the base rate of infection is very low.

Contamination is less of a concern with the ID NOW than with highly sensitive lab-based PCR systems. The amplification happens inside a sealed cartridge, and the workflow does not involve the same open-tube transfer steps that create contamination risk in a high-throughput PCR lab. The trade-off, again, is that the sealed cartridge system processes one sample at a time, making it poorly suited for the kind of batch processing that central laboratories use to handle hundreds of specimens per shift.

How the ID NOW Fits into the Testing Landscape

Thinking of diagnostic tests as falling into neat categories of “PCR” and “antigen” was always a simplification. The ID NOW belongs to a growing family of isothermal molecular tests that borrow the core advantage of PCR (nucleic acid amplification) while ditching the equipment complexity. Other isothermal methods like loop-mediated isothermal amplification (LAMP) work on similar principles, though the specific enzymes and amplification strategies differ.

For you as a patient or consumer, the practical takeaway is straightforward. If you get tested on an ID NOW, you are receiving a molecular test with sensitivity that sits between a rapid antigen strip and a full lab PCR. A positive result is highly reliable. A negative result is trustworthy if you have symptoms and are in the acute phase of illness, but less so if you are asymptomatic or being screened “just in case.” If a negative ID NOW result does not match what you are experiencing clinically, a follow-up PCR is the reasonable next step, and many clinical protocols were designed with exactly that contingency in mind. The device was never meant to replace laboratory PCR entirely. It was built to put molecular-quality testing where decisions are being made in real time, from emergency departments to urgent care clinics, accepting a modest sensitivity trade-off in exchange for answers in minutes instead of hours.